Total Health

 

Total Health is the largest provider of free cancer care resources for people who are treating or living with cancer. Our programs arm cancer care teams with the latest research and strategies to improve patient outcomes.

For more info visit our website at Total Health.

 

Denver
14:05

2020 ASCO Virtual Direct™ Highlights

ASCO 2020 Update on ctDNA Testing: What Are the Clinical Uses of ctDNA and Potential Drawbacks? What Are the MONALEESA Trial Outcomes?

FEATURING Gregory Botta
  • 14 views
  • February 11, 2021
05:43

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on cfDNA Analysis Among Carcinoma of Unknown Primary Patients: What Are Genomic Targets of Interest Based on OncoKB Annotation?

FEATURING Gregory Botta
  • 14 views
  • February 11, 2021
08:38

2020 ASCO Virtual Direct™ Highlights

ASCO 2020 Update on ctDNA & MRD Testing in mCRPC: What Is Prognostic Value of Plasma cfDNA Useful in GMB Patients? What Are the Limitations?

FEATURING Gregory Botta
  • 8 views
  • February 11, 2021
10:05

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on ctDNA and MRD Testing: What Is the Post-Therapy Relapse Risk in ctDNA-Positive Patients? Can ctDNA Analysis Help Guide Treatment Decisions?

FEATURING Gregory Botta
  • 6 views
  • February 11, 2021
11:09

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on HER2+ mBC: Does T-DXd Dosage Change How Effective and Safe It Is? Is Tucatinib/Trastuzumab/Capecitabine Combo Beneficial for PFS?

FEATURING Anthony Elias
  • 72 views
  • December 1, 2020
07:38

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Updates on mBC: What Are the Response Rates With Olaparib? Does Palbociclib Improve PFS in Combination With Fulvestrant/Letrozole in ER+ Disease?

FEATURING Anthony Elias
  • 21 views
  • December 1, 2020
06:45

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Updates on 1L mTNBC: Does Pembro+Chemo Improve PFS vs. Chemo Alone?

FEATURING Anthony Elias
  • 12 views
  • December 1, 2020
06:28

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on Locally Advanced Oropharynx Cancer: Can TORS Reduce the Late Toxicities? Does It Affect PFS?

FEATURING Emrullah Yilmaz
  • 9 views
  • September 29, 2020
06:44

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Updates on HNSCC: Is There a Difference Between Weekly & 3-Weekly Cisplatin?

FEATURING Emrullah Yilmaz
  • 31 views
  • September 29, 2020
10:11

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Updates on R/M ACC & Tumors With HRAS Mutations: Axitinib vs. Observation - What Are the PFS/OS Rates? What Does the Genomic Analysis Suggest? Is FTase Inhibitor Tipifarnib Safe?

FEATURING Emrullah Yilmaz
  • 19 views
  • September 29, 2020
08:56

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on Advanced Prostate Cancer: Is Relugolix Better Tolerated Than Leuprolide Acetate?

FEATURING Brad Somer
  • 15 views
  • September 27, 2020
13:12

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Updates on PSMA in Prostate Cancer: How Useful Is 18F-DCFPyL PET/CT for Recurrent Disease Detection? Are PSA Response Rates Higher With 177Lu-PSMA-617 vs. Cabazitaxel?

FEATURING Brad Somer
  • 12 views
  • September 27, 2020
11:01

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Updates on CRPC: Apalutamide vs. Enzalutamide vs. Darolutamide - What Are the MFS/OS Results for nmCRPC? How Does FDA Approved Rucaparib Work in Patients With BRCA Mutated Disease?

FEATURING Brad Somer
  • 13 views
  • September 27, 2020
21:58

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on Targeted Therapy in Early Stage EGFR+ NSCLC: Adjuvant Osimertinib, Adjuvant EGFR TKI Gefitinib vs. Standard Chemo

FEATURING Millie Das
  • 17 views
  • September 22, 2020
06:43

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Updates on IO in NSCLC: Does Neoadjuvant Durvalumab Add Value to Standard Chemotherapy? Is IO Atezolizumab a Feasible and Safe Addition to SABR?

FEATURING Millie Das
  • 89 views
  • September 22, 2020
05:21

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on KEAP1/NFE2L2 Mutations in Localized NSCLC: Can Genotyping KEAP1/NFE2L2 Mutations Help Facilitate Treatment Personalization?

FEATURING Millie Das
  • 65 views
  • September 22, 2020
  • 1
07:47

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Advanced Melanoma: Does Triplet Regimen Improve PFS in BRAF V600E/K Disease?

FEATURING Adil Daud
  • 177 views
  • August 6, 2020
  • 1
07:25

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Melanoma: Is There a Significant Antitumor Activity for Low-dose Ipilimumab + Pembrolizumab Immediately Following Progression on PD-1 Ab?

FEATURING Adil Daud
  • 49 views
  • August 24, 2020
09:06

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Long-term Follow Up on TILs in Metastatic Melanoma: Is Lifileucel Effective in Refractory Disease?

FEATURING Adil Daud
  • 85 views
  • August 24, 2020
07:41

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on IO in Metastatic Melanoma: Is the Addition of Ipilimumab to anti- PD-1 Beneficial in Patients Resistant to PD-1 Monotherapy?

FEATURING Adil Daud
  • 58 views
  • August 6, 2020
20:35

2020 ASCO Virtual Direct™ Highlights

ASCO 2020 CLL Updates: Should Everyone Get Ibrutinib?

FEATURING Manali Kamdar
  • 456 views
  • August 24, 2020
  • 3
12:40

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Updates on DLBCL: What Is the Optimal Venetoclax Dosing w/ EPOCH That Allows Dose Escalation w/o Venetoclax Reduction? Is Auto SCT in R/R DLBCL Pts Achieving Only a PET/CT+ Partial Remission Appropriate in CAR-T Era?

FEATURING Manali Kamdar
  • 121 views
  • August 24, 2020
  • 1
04:47

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Indolent Lymphoma: Obinutuzumab + Chemo vs. Rituximab + Chemo - Is Clinically Meaningful and Durable Benefit With G-Chemo Relative to R-Chemo? How Beneficial Is Axi-Cel?

FEATURING Manali Kamdar
  • 210 views
  • August 24, 2020
  • 2
04:36

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Hodgkin Lymphoma: Is Pembrolizumab a Better Option Than Brentuximab in R/R Hodgkin Patients Post ASCT Or Ineligible for ASCT?

FEATURING Manali Kamdar
  • 27 views
  • August 24, 2020
11:09

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Advanced Bladder Cancer: Can We Consider Avelumab 1L Maintenance a New SoC?

FEATURING Manojkumar Bupathi
  • 58 views
  • August 13, 2020
09:36

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Ovarian Cancer Secondary Debulking: Is There a Survival Advantage for Surgery in Women With Recurrent Platinum Sensitive Ovarian Cancer?

FEATURING Bradley Corr
  • 19 views
  • August 18, 2020
08:40

2020 ASCO Virtual Direct™ Highlights

2020 ASCO on Ovarian Cancer & GTT: Does Olaparib Maintenance Improve Outcomes in Relapsed Ovarian Cancer? Is There a Role for Avelumab in Gestational Trophoblastic Tumors With Resistance to Single-Agent Chemotherapy?

FEATURING Bradley Corr
  • 37 views
  • August 18, 2020
06:37

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Uterine Serous Carcinoma: How Promising is Adavosertib Monotherapy? Is HER2 Positivity Associated With Worse Outcomes?

FEATURING Bradley Corr
  • 73 views
  • August 18, 2020
07:23

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on HR+ BC: Fulvestrant / Fulvestrant + Anastrozole vs. Anastrozole - Which Option Significantly Improved Endocrine-sensitive Disease Rate in Postmenopausal Women With Locally Advanced BC?

FEATURING Reshma L. Mahtani
  • 126 views
  • August 6, 2020
06:29

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on HR+ BC: Is There a Prognostic Utility of MammaPrint for CT Untreated C-High/G-Low Risk Women After 8.7 Years?

FEATURING Reshma L. Mahtani
  • 94 views
  • August 19, 2020
09:38

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on HER2+ BC: Does Replacing Adjuvant Taxane & Trastuzumab With T-DM1 Improve Efficacy? Do Higher-risk Stage II and III Patients Require Anthracyclines-containing Regimen?

FEATURING Reshma L. Mahtani
  • 322 views
  • August 19, 2020
  • 1
08:28

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on BC: Does Maintenance Therapy With Metronomic Capecitabine Significantly Improve DFS in Operable TNBC? Is There Survival Benefit With Early Local Therapy?

FEATURING Reshma L. Mahtani
  • 195 views
  • August 19, 2020
12:28

2020 ASCO Virtual Direct™ Highlights

2020 ASCO mRCC Highlights: Does the Updated KEYNOTE-426 Analysis Support Pembrolizumab + Axitinib Superiority Over Sunitinib? Does Tumor Shrinkage Correlate With OS?

FEATURING Manojkumar Bupathi
  • 55 views
  • August 6, 2020
08:36

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Bladder Cancer: Does Adjuvant Atezolizumab Improve DFS in Patients With High-risk MIUC?

FEATURING Manojkumar Bupathi
  • 77 views
  • August 4, 2020